The women’s health market is experiencing steady expansion as healthcare systems worldwide increase their focus on preventive care, reproductive health, menopause management, fertility treatments, and chronic disease management among women. Rising awareness regarding female-specific health conditions, along with stronger government-backed healthcare initiatives, is creating significant demand for innovative therapies and advanced treatment solutions. The global women’s health market size was estimated at USD 53.48 billion in 2025 and is projected to reach USD 75.42 billion by 2033, growing at a CAGR of 5.1% from 2026 to 2033. Market growth can be attributed to the increase in the geriatric population of women and the introduction of new advanced therapeutic applications for women’s health. Increasing investments in healthcare infrastructure, digital health platforms, and personalized medicine are also contributing to the growing adoption of women-focused healthcare services across developed and emerging economies.

Furthermore, favorable policies initiated by governments to improve women’s health and raise awareness are likely to drive market growth during the forecast period. Public health campaigns promoting early diagnosis, contraception awareness, maternal healthcare, and menopause treatment are encouraging more women to seek medical assistance and preventive healthcare services. Pharmaceutical and healthcare companies are increasingly focusing on improving accessibility, affordability, and treatment adherence through advanced drug delivery systems and patient-centric care models. Growing discussions around women’s wellness, hormonal balance, fertility planning, and aging-related disorders are also supporting the long-term expansion of the market. In addition, collaborations between healthcare providers, regulatory bodies, and pharmaceutical companies are helping accelerate product approvals and strengthen healthcare outreach initiatives globally.

Download a free sample copy of the Women’s Health market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

North America dominated the market with the largest revenue share of 42.94% in 2025. The region benefits from advanced healthcare infrastructure, high healthcare expenditure, strong awareness regarding women’s health conditions, and the presence of major pharmaceutical and biotechnology companies. Increased adoption of hormonal therapies, fertility treatments, and preventive healthcare services continues to support regional market growth.
Asia Pacific is expected to grow at the fastest CAGR of 7.0% over the forecast period. Rapid urbanization, improving healthcare infrastructure, rising healthcare awareness among women, and expanding access to medical services are driving market demand across countries in the region. Government initiatives promoting maternal healthcare and reproductive wellness are further contributing to the region’s growth trajectory.
By application, the contraceptives segment accounted for the largest revenue share of 28.17% in 2025. Rising awareness regarding family planning, increased accessibility to contraceptive products, and supportive public health initiatives are driving demand in this segment. The growing preference for modern contraceptive solutions and long-acting reversible contraceptives is also supporting segment expansion.
By drug class, the hormonal therapies segment accounted for the largest revenue share of 40.66% in 2025. Hormonal therapies are widely used for managing menopause symptoms, reproductive disorders, osteoporosis prevention, and hormonal imbalances. Advancements in therapy formulations and drug delivery technologies are further enhancing patient compliance and treatment effectiveness.
By age, the 50 years and above segment is expected to grow at the fastest CAGR of 6.7% over the forecast period. The increasing aging female population and rising prevalence of menopause-related conditions, osteoporosis, and chronic health disorders are significantly contributing to demand for specialized healthcare solutions targeted toward older women.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

Key companies in the market emphasize portfolio breadth, lifecycle management, and regulatory engagement to sustain stable demand across contraception, hormonal therapies, fertility, and menopause care. Innovation is largely incremental, improving safety, delivery, and adherence, while selective partnerships and acquisitions expand niche capabilities. Geographic expansion into emerging markets and participation in public health programs support volume growth. Overall, leading players position women’s health as a resilient, long-term strategic segment aligned with public policy and payer priorities.

Key Women’s Health Companies:

AbbVie, Inc.
Bayer AG
Organon & Co.
Pfizer, Inc.
Theramex
Agile Therapeutics
Amgen, Inc.
Apothecus Pharmaceutical Corp.
Blairex Laboratories, Inc.
Ferring

Explore Grand View Horizon to see global and regional level statistics related to the Women’s Health Market

Grand View Research offers

Focused market intelligence reports on specific geographies or high-growth segments.
Extended forecast timelines for long-term planning.
Competitor Benchmarking and Supply Chain Analysis
Inclusion of regulatory and policy assessments.
Inclusion of custom data models, KPIs, or applications unique to your business
Specific high-impact Data Decks and Tables to support effective decision making
And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering

North America Leads Revenue Share in Women’s Health Industry Growth

The global women’s health market size was estimated at USD 53.48 billion in 2025 and is projected to reach USD 75.42 billion by 2033, growing at a CAGR of 5.1%